Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Zantac prevention claim for heartburn, dyspepsia, indigestion proposed in U.K..

This article was originally published in The Tan Sheet

Executive Summary

RANITIDINE OTC TO GAIN HEARTBURN PREVENTION INDICATION IN U.K., according to the Medicines Control Agency's twice-yearly consultation letter on proposals to amend the prescription-only medicines order, released July 24. "Ranitidine has been available as a pharmacy medicine for the short-term symptomatic relief of heartburn, dyspepsia, indigestion, acid indigestion and hyperacidity since 1994," the letter states. "In line with the [Committee on Safety of Medicines'] previous decisions on such substances, we propose to extend the availability of ranitidine as a pharmacy medicine for the prevention of these symptoms when consuming food or drink." Pharmacy medicines are sold behind-the-counter in the U.K.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087384

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel